Cardiovascular Medicine and Haematology articles for Netherlands

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 168

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
1 0.02
Innate type 2 lymphocytes trigger an inflammatory switch in alveolar macrophages 0.02
1 0.79
Raman Microscopy at the Organic–Inorganic Interfaces in Human Calcified Aortic Valves Shows the Co-Existence of Whitlockite Crystals and Carbonated Hydroxyapatite-Mineralized Collagen Fibrils 0.79
1 0.19
Heme iron versus ferrous iron salts to treat iron deficiency anemia in Gambian children: randomized controlled trial 0.19
11 2.04
From mild-to-moderate to severe asthma: Risk factors and patient profiles from the NORDSTAR cohort 0.03
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial 0.08
Mast Cells and Endothelial Cells Mediate Interleukin-33 and ST2 Responses in Distal COPD Lungs 0.18
International validation of electronic nose technology as diagnostic tool for fibrotic interstitial lung diseases 0.36
Upper Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE Study. 0.04
Randomized Sham Controlled Trial of Targeted Lung Denervation in Patients with COPD (AIRFLOW-3). 0.10
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial. 0.06
Inflammation and Obesity Correlate in Pulmonary Hypertension but Associate with Diverging Outcomes. 0.03
Right Ventricular Strain and Outflow Tract Velocity Time Integral Are Associated with Mortality in Critically Ill Patients with Pulmonary Embolism 0.09
The Plasma Proteome in Community-acquired Pneumonia: Pathophysiology, Outcome and 10-Year Risk. 0.93
Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study 0.13
1 0.15
The role of Blended Learning in Enhancing Self-Efficacy and Medication Adherence in Cardiac Rehabilitation for Patients Undergoing Coronary Artery Bypass Surgery: A Randomised Control Trial Blended learning in cardiac rehabilitation 0.15
2 0.26
Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database 0.06
Distinct natural killer cell signature in still's disease: Insights from a multinational immunome project consortium for autoinflammatory disorders 0.20
3 1.24
A novel cause of type 1 Von Willebrand Disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variants 0.58
Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF 0.52
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL 0.14
2 0.14
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis 0.02
Dominant rhabdomyolysis linked to a recurrent ATP2A2 variant reducing SERCA2 function in muscle 0.12
1 0.08
Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammation 0.08
7 1.06
The Impact of Disease Severity and Symptoms on Anxiety and Depression in Individuals With Idiopathic Pulmonary Fibrosis 0.29
Management and Long-Term Outcomes of Persistent Tachypnea of Infancy/Neuroendocrine Cell Hyperplasia of Infancy: A European Multicenter Retrospective Study 0.02
Sex does not modify prediction of asthma attacks by clinical risk factors and Type-2 biomarkers 0.17
Exacerbation Risk by Chronic Proton Pump Inhibitor use in Obstructive Lung Diseases 0.25
Incidence of new comorbidities after steroid use in patients with sarcoidosis: an international cross-sectional survey 0.07
International stakeholder engagement on clinical care and research for sleep assessment and nocturnal hypoxaemia in pulmonary fibrosis 0.12
Airway Mucus Plugging in Chronic Bronchitis and the Impact of Bronchial Rheoplasty 0.14
14 1.48
The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis. 0.06
Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis. 0.03
Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. 0.05
Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation. 0.07
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. 0.01
Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome. 0.05
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome 0.17
Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade. 0.15
Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial. 0.06
Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy. 0.10
Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. 0.09
Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. 0.10
Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis 0.03
Family Screening in Relatives at Risk for Plakophilin-2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy. 0.54
1 0.14
Associations between antibiotic use and outcomes in patients hospitalized with community-acquired pneumonia and positive respiratory viral assays 0.14
1 1.00
Physiological Effects of High-Flow Nasal Oxygen Compared With Conventional Oxygen Therapy: A Randomized Trial in Postextubation Patients. 1.00
2 1.10
Lifetime urban exposure, socioeconomic position and respiratory health among adolescents 0.10
The association between outdoor noise and temperature exposure with incident type 2 diabetes, and mediation by sleep and body mass index: A multi-cohort analysis 1.00
34 10.40
Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome 0.21
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials 0.56
PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study 0.10
Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry 0.01
Sex differences in cardiovascular–kidney–metabolic syndrome: the FINE-HEART pooled analysis 0.03
Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model 0.28
Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model 0.24
Laminopathies: natural history and risk prediction of heart failure 0.04
SLC4A3-related short QT syndrome assessed in human induced pluripotent stem cell-derived cardiomyocytes: mechanisms of ventricular arrhythmia and sudden cardiac death 0.01
Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy 0.87
Arrhythmias in congenitally corrected transposition of the great arteries: an international study 0.03
Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial 0.06
Subvalvular aortic stenosis in adults: clinical course and long-term outcomes 1.00
Left bundle branch vs biventricular pacing: mechanistic insights from a canine model 0.10
Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score 0.04
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification 0.27
Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry 0.04
Outcomes of moderate mixed aortic valve stenosis and regurgitation 0.45
Atrial cardiomyopathy: markers and outcomes 0.48
Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study 0.13
Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation 0.03
Surgical myectomy for hypertrophic cardiomyopathy: procedural volume and outcomes 1.00
Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure 0.10
iLIPA/i, a risk locus for coronary artery disease: decoding the variant-to-function relationship 0.04
Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial 0.65
Titin-related familial dilated cardiomyopathy: factors associated with disease onset 0.18
Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction 0.09
Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis 0.06
Colchicine for secondary prevention of vascular events: a meta-analysis of trials 0.28
First myocardial infarction: risk factors, symptoms, and medical therapy 0.04
Patient–prosthesis mismatch after aortic valve replacement: one size does not fit all 0.83
Plaque erosion: unmasking the complexity of atherosclerotic disease 1.00
Titanium-nitride-oxide-coated vs. drug-eluting stents in acute coronary syndromes: an individual patient data meta-analysis 0.15
Gut microbiota as predictors of recurrent cardiovascular events: challenges and future directions 1.00
1 0.02
Influenza hijacks myeloid cells to inflict type-I interferon-fueled damage in the heart 0.02
1 0.07
SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes 0.07
7 2.72
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy 0.04
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia 0.08
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 0.01
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 0.02
Proactive vs Reactive Treatment of Hypotension During Surgery 0.92
Individualized Prediction of Platelet Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia 0.85
Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease 0.80
1 0.04
Patient-Derived Xenograft Models of Fanconi Anemia-Associated Head and Neck Cancer Identify Personalized Therapeutic Strategies 0.04
1 0.75
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma. 0.75
1 0.89
Interferon-gamma production defects characterise immune responses in patients with chronic pulmonary aspergillosis 0.89
6 3.36
Longer action potential duration in the Purkinje network than in the ventricular myocardium delays retrograde activation of the human His‐Purkinje system 0.50
Unveiling sex dimorphism in the healthy cardiac anatomy: Fundamental differences between male and female heart shapes 0.27
Mathematical model of the zebrafish ventricular cardiomyocyte action potential and calcium transient 0.17
The influence of delayed ventricular activation on cardiac repolarization: Insights from electrocardiographic imaging 0.80
Computational modelling of the pro‐ and antiarrhythmic effects of atrial high rate‐dependent trafficking of small‐conductance calcium‐activated potassium channels 0.63
Loss of wall stress homoeostasis in ascending thoracic aortic aneurysm: histomorphometric insights into patient variants 1.00
4 1.18
Microinvasive, off-pump, transventricular neochordae implantation in recurrent mitral valve regurgitation after open heart surgical repair 0.07
Pulmonary valve repair at the time of the Ross procedure: a safe and durable strategy to address post-implantation aortic regurgitation 0.06
Oral anticoagulation in patients with atrial fibrillation and heart valve prosthesis: a substudy from the LAAOS III Trial 0.13
Personalized External Aortic Root Support, the Dutch Experience 0.93
17 4.65
Risk-Based Nurse-Managed Personalized Heart Failure Interventions 0.06
Effectiveness and Safety of Early Rhythm Control in Patients With Atrial Fibrillation and Chronic Kidney Disease 0.07
Aligning Coronary Stent Trial Enrollment With the U.S. Intended-Use Population 0.05
Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study 0.16
Cardiovascular Disease Risk in Adults With Hematological Malignancies 0.89
Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation 0.05
Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch A Randomized Controlled Trial 0.95
Echocardiographic Diastolic Function Grading in HFpEF Testing the Updated 2025 ASE Criteria 0.11
One-year outcomes of novel balloon-expandable versus contemporary transcatheter heart valves in severe aortic stenosis: the LANDMARK trial 0.12
Proactive Management and Treatment of Aortic Stenosis: An International Expert Perspective 0.03
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients A Pooled Analysis 0.50
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation Results in 18,000 Clinical Trial Participants 0.02
Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial 0.56
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR 0.04
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global Trials 0.04
Relationship Between Exercise-Induced Cardiac Troponin Elevations and Occult Coronary Atherosclerosis in Middle-Aged Athletes 0.96
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension Results of an International Multicenter Prospective Registry 0.03
2 0.14
Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone. 0.06
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. 0.08
2 0.18
Polygenic risk of coronary artery disease for long-term survivors of breast cancer 0.03
Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention 0.14
10 2.57
Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesis 0.03
Precision cardiovascular risk prediction in type 1 diabetes: An IMI2 SOPHIA analysis 0.02
NK cells promote cardiac cell death and regulate myelopoiesis in myocardial infarction 0.01
A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases 0.01
Clusters of vascular aging manifestations predict incident cardiovascular events in the community 0.41
Endoglin as a BMP9 co-receptor in vascular endothelial cells: prodomain displacement and TGFBRII recruitment 0.14
Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes 0.18
Hypoxic conditioning in Parkinson’s disease: randomized controlled multiple N-of-1 trials 0.71
Lung structural cells are altered by infeluenza virus leading to rapid immune protection following re-challenge 0.05
Normothermic human kidney preservation drives iron accumulation and ferroptosis 1.00
1 1.00
Blood vessel-resident macrophages safeguard blood and vessel integrity in zebrafish 1.00
9 1.65
The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial 0.07
Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial 1.00
Predicting referral need for febrile children in low-resource community settings in South and Southeast Asia 0.01
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial 0.05
The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial 0.08
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial 0.30
Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial 0.10
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.00
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial 0.04
1 0.04
Super-Resolution Deep Learning Reconstruction for Coronary CT Angiography: Coronary Stenosis Assessment and CAD-RADS Reclassification. 0.04
2 0.02
Targeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapy 0.01
Resistin-like molecule γ attacks cardiomyocyte membranes and promotes ventricular tachycardia 0.02
1 0.06
Extracellular BRICK1 drives heart repair after myocardial infarction in mice 0.06
2 1.02
Prognostic score for predicting respiratory admissions among patients with chronic obstructive pulmonary disease in primary care: development and validation in population cohorts (Birmingham Lung Improvement Studies (BLISS)) 0.13
Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis 0.89
3 0.58
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years 0.05
Nasal gene expression shows a distinct signature in T2-high asthma but not in T2-low disease 0.38
Genetic characterization of preschool wheeze phenotypes 0.15
6 1.29
Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial 1.00
Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial 0.13
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial 0.03
Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials 0.06
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials 0.03
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial 0.03
6 0.96
Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage 0.04
Angiography-Based Physiology to Guide Coronary Revascularization 0.24
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia 0.09
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke 0.04
Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction 0.45
Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction 0.10
2 0.36
Association of blood eosinophils and exhaled nitric oxide with exacerbations in patients with asthma, COPD and asthma+COPD: the NOVELTY study 0.21
Transcriptomic signatures of IPF in ALI-cultured airway cells and their therapeutic implications 0.14

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.